Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Latest Information Update: 30 Mar 2022
At a glance
- Drugs SGS 742 (Primary)
- Indications Inborn error amino acid metabolic disorders
- Focus Therapeutic Use
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Planned End Date changed from 31 Jan 2019 to 31 Jan 2020.
- 13 Jul 2018 Planned End Date changed from 30 Nov 2018 to 31 Jan 2019.